Published: 2026-03-03 00:03
NICE Issues Guidance on Antiviral Molnupiravir for COVID-19
The National Institute for Health and Care Excellence (NICE) has published new technology appraisal guidance (TA1056) concerning the use of molnupiravir for treating COVID-19. This guidance provides clarity for healthcare professionals in England on the appropriate use of this oral antiviral, aiming to ensure that it is directed towards patients most likely to benefit from treatment.
The appraisal outlines specific criteria for the prescription of molnupiravir, underscoring its role in preventing severe illness in vulnerable individuals. As the COVID-19 treatment landscape continues to evolve, guidance from bodies like NICE is vital in optimising patient care and resource allocation within the NHS.
Understanding Molnupiravir
Molnupiravir is an oral antiviral agent designed to treat mild-to-moderate COVID-19 in adults. It functions by introducing errors into the SARS-CoV-2 viral RNA during replication, thereby inhibiting the virus’s ability to multiply effectively within the body. This mechanism aims to reduce viral load and the risk of progression to severe disease.
The medicine received a conditional marketing authorisation in the UK in November 2021 for use in adults with mild-to-moderate COVID-19 and at least one risk factor for developing severe illness. Its oral formulation offers a significant advantage for outpatient treatment compared to intravenous alternatives.
Implications for Healthcare Professionals
Key Recommendations for Clinical Use
NICE’s guidance specifies the patient population for whom molnupiravir is recommended, emphasising a targeted approach based on clinical need and risk factors. The appraisal considers the evidence on molnupiravir’s effectiveness in reducing the risk of hospitalisation or death and its cost-effectiveness within the NHS.
The guidance recommends molnupiravir as an option for treating COVID-19 in adults who meet certain criteria. These typically include:
- A confirmed diagnosis of mild-to-moderate COVID-19, based on a positive SARS-CoV-2 test.
- Onset of COVID-19 symptoms within the last five days.
- Being aged 18 years or older.
- Having one or more risk factors for progressing to severe COVID-19.
It is particularly relevant for those considered to be at high risk of severe outcomes, for whom other first-line antiviral treatments, such as nirmatrelvir/ritonavir, may be contraindicated or not suitable.
Defining ‘High Risk’
The definition of ‘high risk’ for progression to severe COVID-19 is crucial for appropriate prescribing. While specific details should always be checked against the full NICE document, categories of patients typically considered at high risk often include:
- Individuals with significant immunosuppression, whether due to disease (e.g., haematological malignancies, advanced HIV) or medication (e.g., high-dose systemic corticosteroids, recent chemotherapy).
- Those with certain chronic conditions, such as severe respiratory disease, significant cardiovascular disease, chronic kidney disease, or chronic liver disease.
- Patients with neurological conditions that increase the risk of respiratory complications.
- Other specific medical conditions or treatments identified as increasing vulnerability to severe COVID-19.
Healthcare professionals are advised to refer to the comprehensive eligibility criteria outlined in the NICE guidance and accompanying clinical protocols to ensure accurate patient selection.
Positioning in the COVID-19 Treatment Landscape
Evidence Base Reviewed by NICE
NICE’s recommendations are grounded in a rigorous assessment of clinical trial data and economic modelling. The primary evidence considered for molnupiravir includes findings from the MOVe-OUT study, a phase 3 randomised, placebo-controlled trial.
This study evaluated the efficacy and safety of molnupiravir in non-hospitalised adults with mild-to-moderate COVID-19 who had at least one risk factor for progression to severe disease. The key outcome measures typically assessed were the rates of hospitalisation or death from any cause up to 29 days after randomisation.
The trial results indicated that molnupiravir significantly reduced the risk of hospitalisation or death compared to placebo in this patient group when administered early in the course of illness. NICE’s appraisal considers not only the clinical effectiveness but also how molnupiravir compares with existing therapeutic options and its cost-effectiveness for the NHS.
The appraisal process also takes into account:
- The overall safety profile of the drug.
- Patient experience and preferences where available.
- Uncertainties and limitations in the evidence.
- The cost of the medicine in relation to the benefits it provides.
Positioning in the COVID-19 Treatment Landscape
Molnupiravir joins a suite of treatments available for COVID-19 in the UK, which includes other oral antivirals, intravenous antivirals like remdesivir, and monoclonal antibodies. Its place within this treatment algorithm is primarily as an early intervention for high-risk, non-hospitalised patients.
The choice between available antivirals often depends on individual patient factors, including comorbidities, potential drug-drug interactions, and contraindications. For instance, nirmatrelvir/ritonavir may be the preferred first-line oral antiviral for many eligible patients, but its use can be restricted by significant interactions with commonly prescribed medications. In such scenarios, molnupiravir offers an important alternative.
| Antiviral Feature | Molnupiravir | Nirmatrelvir/Ritonavir (e.g., Paxlovid) |
|---|---|---|
| Mechanism of Action | RNA polymerase inhibitor (introduces errors) | Protease inhibitor (nirmatrelvir) + CYP3A inhibitor (ritonavir) |
| Administration Route | Oral | Oral |
| Target Population | High-risk adults with mild-to-moderate COVID-19, where other options may not be suitable. | High-risk adults with mild-to-moderate COVID-19. |
| Key Consideration | Alternative when other treatments are contraindicated/unsuitable. | Potential for significant drug-drug interactions with ritonavir component. |
| Initiation Window | Within 5 days of symptom onset. | Within 5 days of symptom onset. |
This comparative overview highlights how different antivirals serve distinct, yet sometimes overlapping, roles in managing COVID-19, requiring clinicians to exercise careful judgement in selecting the most appropriate agent for each patient.
Positioning in the COVID-19 Treatment Landscape
Implications for Healthcare Professionals
The NICE guidance underscores the importance of a streamlined pathway for identifying eligible patients and initiating treatment promptly. Healthcare professionals, including general practitioners, pharmacists, and hospital teams, play a critical role in this process.
Key considerations for clinicians include:
- Early Identification: Recognising patients at high risk of severe COVID-19 who could benefit from antiviral treatment.
- Timely Diagnosis: Ensuring prompt access to SARS-CoV-2 testing for symptomatic high-risk individuals.
- Rapid Assessment: Evaluating patient eligibility against the NICE criteria, including symptom onset date and comorbidities.
- Drug Interaction Checks: Although molnupiravir has fewer drug interaction concerns than nirmatrelvir/ritonavir, a thorough medication review remains important.
- Patient Education: Informing patients about the treatment, its benefits, and potential side effects.
Adherence to this guidance is crucial for optimising patient outcomes and ensuring consistent care across the NHS. It also helps manage expectations regarding the availability and suitability of specific treatments.
Looking Ahead
As the COVID-19 virus continues to evolve, and new treatments emerge, NICE periodically reviews and updates its guidance to reflect the latest evidence and clinical practice. Healthcare professionals are encouraged to stay informed of these updates to provide the best possible care for patients affected by COVID-19. The availability of oral antivirals like molnupiravir represents a significant advancement in the outpatient management of the disease, particularly for those at highest risk.
Source: NICE
